"The analyses of the CKD and low LDL-C subgroups were pre-specified, not post-hoc. CHF was pre-specified outcome. SGLT2 inhibitor subgroup is post-hoc I believe. "

Yes, perhaps I did not frame my thought correctly, so that said, do we have enough sub-group analysis for FDA to approve what we have in hand to take it to market with not having to run around the block (so to speak) one more time needing a lot more cash and more time to get there.

Let's hope the FDA  sees some promise with some of the analyses to minimize our efforts to capitalize on our investment sooner rather than later.  

IMO...Koo